Drug Approval | August 16, 2023
Eugia Pharma receives USFDA Approval for Icatibant Injection
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
The product is being launched in August 2023
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
This product will be launched through Granules Consumer Health (GCH) division
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Granules now has a total of 58 ANDA approvals from US FDA
Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.
Subscribe To Our Newsletter & Stay Updated
